オキシフェンブタゾン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H400：水生生物に強い毒性

• 注意書き

  P273：環境への放出を避けること。

オキシフェンブタゾン 価格

オキシフェンブタゾン 化学特性,用途語,生産方法

• 効能

  鎮痛薬, 抗炎症薬, 解熱薬, 抗リウマチ薬, シクロオキシゲナーゼ阻害薬

• 化学的特性

  Light Beige Solid

• 使用

  Anti-inflammatory;Cyclooxygenase inhibito

• 適応症

  Oxyphenbutazone (Oxalid, Tandearil) is the principal uricosuric metabolite of phenylbutazone. It has the same indications and toxicities as phenylbutazone.

• 定義

  ChEBI: A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following asso iation with blood dyscrasis and Stevens-Johnson syndrome.

• 世界保健機関（WHO）

  Oxyphenbutazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1955 for the treatment of rheumatic disorders. It is one of the active metabolites of phenylbutazone and has a similar spectrum of activity including an association with serious and sometimes fatal adverse reactions, notably cases of aplastic anaemia and agranulocytosis. Many national drug regulatory authorities consider that more recently introduced drugs offer a safer alternative for most, if not all, patients requiring antiinflammatory agents. Although oxyphenbutazone has been widely withdrawn it remains available in some countries.

• 一般的な説明

  Oxyphenbutazone is a derivative compound of phenylbutazone. Oxyphenbutazone is one of the metabolites formed in the liver following administration of phenylbutazone. Given orally it causes fewer gastrointestinal adverse effects than phenylbutazone and is used at 300 – 400 mg/d for the same indications as the parent drug.

オキシフェンブタゾン 上流と下流の製品情報

オキシフェンブタゾン 生産企業

Global(70)Suppliers

129-20-4, オキシフェンブタゾン キーワード